Vancomycin-Resistant Enterococcus Faecium Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Vancomycin-Resistant Enterococcus Faecium Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Drugs In Development, 2022, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.

Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 2, 14 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.

Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Vancomycin-Resistant Enterococcus faecium Infections – Overview
Vancomycin-Resistant Enterococcus faecium Infections – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Vancomycin-Resistant Enterococcus faecium Infections – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vancomycin-Resistant Enterococcus faecium Infections – Companies Involved in Therapeutics Development
Acurx Pharmaceuticals Inc
Aphios Corp
Arietis Corp
Curza Global LLC
Daiichi Sankyo Co Ltd
Gnubiotics Sciences SA
Hsiri Therapeutics LLC
Karveel Pharmaceuticals
MetalloBio Ltd
MGB Biopharma Ltd
MicuRx Pharmaceuticals Inc
Naicons Srl
NovoBiotic Pharmaceuticals LLC
Opal Biosciences Ltd
Oragenics Inc
QureTech Bio AB
Rebiotix Inc
Sano Chemicals Inc
Sentinella Pharmaceuticals Inc
Seres Therapeutics Inc
Taisho Pharmaceutical Holdings Co Ltd
Wockhardt Ltd
Vancomycin-Resistant Enterococcus faecium Infections – Drug Profiles
ACX-375C – Drug Profile
APY-281 – Drug Profile
BDM-I – Drug Profile
contezolid – Drug Profile
contezolid acefosamil – Drug Profile
GCX/GBX – Drug Profile
GmPcide-1 – Drug Profile
HT-01 – Drug Profile
HT-02 – Drug Profile
IBN-1 – Drug Profile
Marinus – Drug Profile
MGBBP-3 – Drug Profile
MUT-001 – Drug Profile
NAI-107 – Drug Profile
NAI-108 – Drug Profile
NAI-603 – Drug Profile
Novo-29 – Drug Profile
OG-253 – Drug Profile
RBX-2660 – Drug Profile
RuTMP – Drug Profile
SER-155 – Drug Profile
Small Molecule for Gram-Positive Bacterial Infections – Drug Profile
Small Molecules for Bacterial Infections – Drug Profile
Small Molecules for Gram-Positive Bacterial Infections – Drug Profile
Small Molecules for VRE Infections – Drug Profile
Small Molecules to Activate CLPP for Vancomycin Resistant Enterococci Infections – Drug Profile
Small Molecules to Inhibit ftsz for Infectious Disease – Drug Profile
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections – Drug Profile
SNP-021062 – Drug Profile
Synthetic Peptide to Disrupt Bacterial Cell Membrane for Bacterial Infections – Drug Profile
TP-0480066 – Drug Profile
WCK-4086 – Drug Profile
Vancomycin-Resistant Enterococcus faecium Infections – Dormant Projects
Vancomycin-Resistant Enterococcus faecium Infections – Discontinued Products
Vancomycin-Resistant Enterococcus faecium Infections – Product Development Milestones
Featured News & Press Releases
Nov 26, 2018: MicuRx enrolls first patient in a phase 2 clinical trial in U.S. for novel antibiotic, Contezolid Acefosamil
Nov 29, 2016: MicuRx Initiates Phase 1 Clinical Trial in U.S. for Novel Antibiotic Agent MRX-4
Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent
Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
Table 4: Number of Products under Development by Universities/Institutes, 2022
Table 5: Products under Development by Companies, 2022
Table 6: Products under Development by Companies, 2022 (Contd..1)
Table 7: Products under Development by Universities/Institutes, 2022
Table 8: Number of Products by Stage and Target, 2022
Table 9: Number of Products by Stage and Mechanism of Action, 2022
Table 10: Number of Products by Stage and Route of Administration, 2022
Table 11: Number of Products by Stage and Molecule Type, 2022
Table 12: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Acurx Pharmaceuticals Inc, 2022
Table 13: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Aphios Corp, 2022
Table 14: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Arietis Corp, 2022
Table 15: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Curza Global LLC, 2022
Table 16: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Daiichi Sankyo Co Ltd, 2022
Table 17: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Gnubiotics Sciences SA, 2022
Table 18: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Hsiri Therapeutics LLC, 2022
Table 19: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Karveel Pharmaceuticals, 2022
Table 20: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by MetalloBio Ltd, 2022
Table 21: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by MGB Biopharma Ltd, 2022
Table 22: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by MicuRx Pharmaceuticals Inc, 2022
Table 23: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Naicons Srl, 2022
Table 24: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by NovoBiotic Pharmaceuticals LLC, 2022
Table 25: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Opal Biosciences Ltd, 2022
Table 26: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Oragenics Inc, 2022
Table 27: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by QureTech Bio AB, 2022
Table 28: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Rebiotix Inc, 2022
Table 29: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Sano Chemicals Inc, 2022
Table 30: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Sentinella Pharmaceuticals Inc, 2022
Table 31: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Seres Therapeutics Inc, 2022
Table 32: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
Table 33: Vancomycin-Resistant Enterococcus faecium Infections – Pipeline by Wockhardt Ltd, 2022
Table 34: Vancomycin-Resistant Enterococcus faecium Infections – Dormant Projects, 2022
Table 35: Vancomycin-Resistant Enterococcus faecium Infections – Dormant Projects, 2022 (Contd..1)
Table 36: Vancomycin-Resistant Enterococcus faecium Infections – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Routes of Administration, 2022
Figure 9: Number of Products by Stage and Routes of Administration, 2022
Figure 10: Number of Products by Molecule Types, 2022
Figure 11: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings